Clinical trial of Russian vaccine Sputnik-V begins in India with Dr. Reddy’s

Dr. Reddy’s Laboratories and the Russian Direct Investment Fund (RDIF) said on Tuesday that they have begun a second-third phase trial of the coronavirus Sputnik-V vaccine in India. They said that the trial has started after getting the necessary clearance from the Central Pharmaceutical Laboratory at Kasauli.

The joint statement said that the trial is taking place in many places. For this, JSS Medical Research has been made a clinical research partner. Dr. Reddy’s has also entered into an agreement to use the Biological Technology Research Assistance Council’s clinical trial centers. The Council’s Biotechnology Department is providing consultation in trials.

Recently, RDIF announced the second interim adjective of clinical trial data showing 91.4 percent efficacy for the vaccine on day 28 after the first dose. In addition, more than 95 percent of efficacy has been reported after 42 days of the first dose. 40,000 volunteers are taking part in the third phase of the Sputnik-V clinical trials, of which more than 22,000 volunteers have been given the first dose of the vaccine. In addition, more than 19,000 people have been given the first and second doses.

Dr. GV, Co-Chairman and Managing Director of Dr. Reddy’s Laboratories Prasad said, “This is another important step, as we continue to collaborate with many bodies along with government bodies to speed up the process of launching vaccines in India. We are working towards providing vaccines in conjunction with import and indigenous production models.” In September 2020, Dr. Reddy’s and RDIF partnered with the clinical trial of Sputnik-V vaccine and the delivery of the initial 100 million doses in India.